CRA International sells economic consulting and expert testimony, mostly to law firms and corporate counsel in antitrust, securities, and commercial litigation, plus regulatory work for energy and healthcare clients. Its edge is a bench of PhD economists and former regulators who can carry a testimony through deposition and trial, a business that tends to renew around case cycles rather than annual budgets. Revenue growth of 12.8% and a 26.0% return on equity are strong for a consulting firm with an 11.2% operating margin, and the stock trades at 17.0 times forward earnings against 23.6 times trailing, so the market is pricing in continued earnings growth. The thesis rests on whether antitrust and regulatory dockets stay busy enough to keep utilization and billing rates rising, and whether the company can convert that demand into margin expansion from its 29.0% gross margin. At a roughly $1.1 billion market cap with no index membership, the name is small enough that a position could be built without moving the price, and it merits a deeper look at utilization trends and headcount before going further.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 24 Oct 2026, 17:04 CEST | Fair value | $140 | $163 | $200 |
| 24 Oct 2026, 17:04 CEST | Rating | Overvalued | first publication | $200 |
| 13 Oct 2026, 00:00 CEST | ACCE price target | $187 | first publication | $177 |
| 12 Oct 2026, 00:00 CEST | Fair value | $163 | $141 | $177 |
| 28 Sept 2026, 00:00 CEST | Fair value | $141 | $143 | $162 |
| 26 Sept 2026, 00:00 CEST | Fair value | $143 | $140 | $163 |
| 23 Sept 2026, 00:00 CEST | Fair value | $140 | $142 | $162 |
| 10 Sept 2026, 00:00 CEST | Fair value | $142 | $145 | $168 |
| 7 Sept 2026, 00:00 CEST | Fair value | $145 | $148 | $171 |
| 4 Sept 2026, 00:00 CEST | Fair value | $148 | $150 | $171 |
Answered from CRA International Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| CRAI CRA International Inc. Common Stock | $200.14 | $140 | 43% above | 26.8x | 26.0% | 74 | 70 |
| IPS.PA Ipsos SA | €35.30 | €60 | 42% below | 8.8x | 11.9% | 67 | 62 |
| ICFI ICF International Inc. Common Stock | $94.40 | $106 | 11% below | 18.8x | 8.6% | 56 | 63 |
| SBC SBC Medical Group Holdings Incorporated Common Stock | $5.28 | $6 | 18% below | 11.2x | 18.9% | 95 | 89 |
| HURN Huron Consulting Group Inc. Common Stock | $195.69 | $146 | 34% above | 28.0x | 26.9% | 69 | 77 |
| BTS-B.ST BTS Group AB (publ) | kr 231.00 | - | - | 47.2x | 6.3% | 60 | 61 |
| FCN FTI Consulting Inc. Common Stock | $157.24 | $166 | 5% below | 18.9x | 15.6% | 64 | 50 |
Where CRAI ranks against its sector peers on each metric.